95 results on '"Seilles E"'
Search Results
2. Surveillance biologique des patients transplantés rénaux : vers une prévision des complications associées à l’immunosuppression ?
- Author
-
Saas, P., Courivaud, C., Bamoulid, J., Garnache-Ottou, F., Seilles, E., and Ducloux, D.
- Published
- 2008
- Full Text
- View/download PDF
3. Increased levels of circulating microparticles and procoagulant activity in melanoma patients: P-246
- Author
-
Laresche, C., Pelletier, F., Garnache-Ottou, F., Lihoreau, T., Biichlé, S., Mourey, G., Saas, P., Humbert, P., Seilles, E., and Aubin, F.
- Published
- 2013
4. Nonspecific secretory immunity in HIV-infected patients with oral candidiasis
- Author
-
Bard, E., Laibe, S., Clair, S., Biichle, S., Millon, L., Drobacheff, C., Bettinger, D., Seilles, E., and Meillet, D.
- Subjects
Epidemiology -- Statistics ,Epidemiology -- Research ,HIV patients -- Case studies ,HIV patients -- Health aspects ,HIV patients -- Care and treatment ,HIV infection -- Prevention ,HIV infection -- Research ,HIV infection -- Health aspects ,Thrush (Mouth disease) -- Care and treatment ,Thrush (Mouth disease) -- Prevention ,Thrush (Mouth disease) -- Health aspects ,Thrush (Mouth disease) -- Causes of ,Health - Abstract
Research has been conducted on nonspecific secretory immunity in HIV-infected patients with oral candidiasis. The study of this immunity has been carried out via measuring lysozyme, lactoferrin, secretory IgA and total IgA levels, and the results demonstrate that despite saliva concentration and good intestinal output innate immunity could not prevent yeast expansion in HIV-infected patients.
- Published
- 2002
5. Les auteurs
- Author
-
Adotévi., O., Amé-Thomas., P., Arnulf., B., Baron., C., Batteux., F., Beauvillain., C., Bérard., F., Blancho., G., Bourdenet., G., Boyer., O., Caillat-Zucman., S., Candon., S., Carapito., R., Carcelain., G., Carnoy., C., Cesbron., J.-Y., Chevailler., A., Chollet-Martin., S., Colombo., B., Contin-Bordes., C., Coutant., F., Dantal., J., de Carvalho Bittencourt., M., de Chaisemartin., L., Delfau-Larue., M.-H., Desplat-Jégo., S., Dragon-Durey., M.-A., Dubucquoi., S., Dumestre-Perard., C., Fischer., A., Fisson., S., Flament., H., Fournel., S., Galaine., J., Garraud., O., Godet., Y., Gorochov., G., Gros., F., Gubler., B., Guffroy., A., Hacein-Bey-Abina., S., Hoarau., C., Hüe., S., Kaplanski., G., Kervella., D., Kolopp Sarda., M.-N., Labalette., M., Lambotte., O., Le Gouvello., S., Le Naour., R., Lelièvre., J.-D., Lemoine., F., Liégeois., S., Martinet., J., Miyara., M., Moins-Teisserenc., H., Molinier-Frenkel., V., Nel., I., Pagès., F., Paul., S., Picard., C., Radosavljevic., M., Renaudineau., Y., Rosain., J., Rosenzwajg., M., Seillès., E., Soulas-Sprauel., P., Sterlin., D., Tartour., É., Taupin., J.-L., Thibault., G., Tiberghien., P., Toubert., A., Visentin., J., Vitte., J., Vivier., É., Watier., H., and Weiss., L.
- Published
- 2023
- Full Text
- View/download PDF
6. Serum secretory immunoglobulins in ankylosing spondylitis
- Author
-
Wendling, D., Didier, J-M., and Seilles, E.
- Published
- 1996
- Full Text
- View/download PDF
7. Function of the oxidative metabolism of phagocytes in elderly people: relationship to nutritional and inflammatory status
- Author
-
Didier, J.M., De Wazieres, B., Becker-Schneider, M., Seilles, E., Dupond, J.L., and Vuitton, D.A.
- Subjects
Phagocytes -- Physiological aspects -- Research ,Aged -- Physiological aspects -- Research ,Oxidative stress -- Research ,Health ,Psychology and mental health ,Seniors ,Social sciences ,Physiological aspects ,Research - Abstract
Introduction Abnormalities in the activation of and production of oxygen-free radicals (OFR) by phagocytic cells may be involved in the pathogenesis of age-related tissue lesions and in alterations of the [...]
- Published
- 1995
8. Angiœdème bradykinique par déficit en C1 Inhibiteur acquis : quatre cas
- Author
-
Jacquin-Porretaz, C., primary, Castelain, F., additional, Daguindau, E., additional, Seilles, E., additional, Nardin, C., additional, Aubin, F., additional, and Pelletier, F., additional
- Published
- 2018
- Full Text
- View/download PDF
9. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent
- Author
-
Angelot-Delettre, F., primary, Roggy, A., additional, Frankel, A. E., additional, Lamarthee, B., additional, Seilles, E., additional, Biichle, S., additional, Royer, B., additional, Deconinck, E., additional, Rowinsky, E. K., additional, Brooks, C., additional, Bardet, V., additional, Benet, B., additional, Bennani, H., additional, Benseddik, Z., additional, Debliquis, A., additional, Lusina, D., additional, Roussel, M., additional, Solly, F., additional, Ticchioni, M., additional, Saas, P., additional, and Garnache-Ottou, F., additional
- Published
- 2014
- Full Text
- View/download PDF
10. L’auto-inflammation dans le psoriasis : rôle des cellules dendritiques
- Author
-
Pelletier, F., Angelot, F., Garnache-Ottou, F., Humbert, P., Seilles, E., and Aubin, F.
- Published
- 2010
- Full Text
- View/download PDF
11. Increased levels of circulating microparticles are associated with increased procoagulant activity in patients with cutaneous malignant melanoma
- Author
-
Laresche, C., primary, Pelletier, F., additional, Garnache-Ottou, F., additional, Lihoreau, T., additional, Biichlé, S., additional, Mourey, G., additional, Saas, P., additional, Humbert, P., additional, Seilles, E., additional, and Aubin, F., additional
- Published
- 2013
- Full Text
- View/download PDF
12. ChemInform Abstract: New 7-Hydroxy-1,3-diazabicyclo(3.3.0)octane Derivatives: Evaluation of Their in vitro Immunomodulating Effects.
- Author
-
ISSARTEL, V., primary, SPEHNER, V., additional, BAHAJI, H., additional, SEILLES, E., additional, and COUQUELET, J., additional
- Published
- 2010
- Full Text
- View/download PDF
13. Endothelial cell-derived microparticles induce plasmacytoid dendritic cell maturation: potential implications in inflammatory diseases
- Author
-
Angelot, F., primary, Seilles, E., additional, Biichle, S., additional, Berda, Y., additional, Gaugler, B., additional, Plumas, J., additional, Chaperot, L., additional, Dignat-George, F., additional, Tiberghien, P., additional, Saas, P., additional, and Garnache-Ottou, F., additional
- Published
- 2009
- Full Text
- View/download PDF
14. Intravenous apoptotic spleen cell infusion induces a TGF-β-dependent regulatory T-cell expansion
- Author
-
Kleinclauss, F, primary, Perruche, S, additional, Masson, E, additional, de Carvalho Bittencourt, M, additional, Biichle, S, additional, Remy-Martin, J-P, additional, Ferrand, C, additional, Martin, M, additional, Bittard, H, additional, Chalopin, J-M, additional, Seilles, E, additional, Tiberghien, P, additional, and Saas, P, additional
- Published
- 2005
- Full Text
- View/download PDF
15. 046 Privilège immunologique, TGF béta2 et greffes de cornée
- Author
-
Lebreton, O., primary, Biichle, S., additional, Seilles, E., additional, Montard, M., additional, and Delbosc, B., additional
- Published
- 2005
- Full Text
- View/download PDF
16. Effect of an auditory stress on peritoneal and alveolar cells in C57 BL/6J mice of advanced age
- Author
-
de Wazieres, B., primary, Harraga, S., additional, Spehner, V., additional, Bloy, Ch., additional, Dupond, J. L., additional, Vuitton, D. A., additional, and Seilles, E., additional
- Published
- 2000
- Full Text
- View/download PDF
17. Améliorer la qualité des textes pour améliorer la qualité des soins : travail linguistique sur des protocoles de prélèvement par aphérèse
- Author
-
Renahy, J., Plaisantin Alecu, B., Prévitali, A., Biichlé, S., Seillès, E., Morel, P., and Vuitton, D.-A.
- Published
- 2013
- Full Text
- View/download PDF
18. New 7-hydroxy-1,3-diazabicyclo[3.3.0]octane derivatives: evaluation of their in vitro immunomodulating effects
- Author
-
Issartel, V, primary, Spehner, V, additional, Bahaji, H, additional, Seilles, E, additional, and Couquelet, J, additional
- Published
- 1996
- Full Text
- View/download PDF
19. ChemInform Abstract: Immunomodulatory Agents. Dioxothiadiazabicyclo(3.3.0)octanes and Their 2‐Spiro Derivatives.
- Author
-
REFOUVELET, B., primary, HARRAGA, S., additional, NICOD, L., additional, ROBERT, J.‐F., additional, SEILLES, E., additional, COUQUELET, J., additional, and TRONCHE, P., additional
- Published
- 1995
- Full Text
- View/download PDF
20. ChemInform Abstract: Imidazo(2,1‐b)thiazole Derivatives. Part 11. Modulation of the CD2‐ Receptor of Human T Trypsinized Lymphocytes by Several Imidazo(2,1‐b) thiazoles.
- Author
-
HARRAGA, S., primary, NICOD, L., additional, DROUHIN, J. P., additional, XICLUNA, A., additional, PANOUSE, J. J., additional, SEILLES, E., additional, and ROBERT, J. F., additional
- Published
- 1994
- Full Text
- View/download PDF
21. Imidazo[2,1-b]thiazole derivatives. XI. Modulation of the CD2-receptor of human T trypsinized lymphocytes by several imidazo[2,1-b]thiazoles
- Author
-
Harraga, S, primary, Nicod, L, additional, Drouhin, JP, additional, Xicluna, A, additional, Panouse, JJ, additional, Seilles, E, additional, and Robert, JF, additional
- Published
- 1994
- Full Text
- View/download PDF
22. Expression du récepteur des immunoglobulines polymères (R. poly Ig ou composante sécrétoire) par les cellules conjonctivales dans la maladie de Gougerot-Sjögren
- Author
-
Rame, J.M., primary, Seilles, E., additional, Kantelip, B., additional, de Wazières, B., additional, Bosc, J.M., additional, Dupond, J.L., additional, Royer, J., additional, and Vuitton, D.A., additional
- Published
- 1991
- Full Text
- View/download PDF
23. Triazinic herbicide determination by gas chromatography–mass spectrometry in breast milk
- Author
-
Balduini, L., Matoga, M., Cavalli, E., Seilles, E., Riethmuller, D., Thomassin, M., and Guillaume, Y.C.
- Published
- 2003
- Full Text
- View/download PDF
24. Intravenous apoptotic spleen cell infusion induces a TGF-β-dependent regulatory T-cell expansion.
- Author
-
Kleinclauss, F., Perruche, S., Masson, E., Bittencourt, M. de Carvalho, Biichle, S., Remy-Martin, J.-P., Ferrand, C., Martin, M., Bittard, H., Chalopin, J.-M., Seilles, E., Tiberghien, P., Saas, P., and Piacentini, M.
- Subjects
LEUCOCYTES ,TRANSPLANTATION of organs, tissues, etc. ,HEMATOPOIETIC growth factors ,MACROPHAGES ,CONNECTIVE tissue cells ,CELLS ,T cells ,APOPTOSIS ,BIOCHEMISTRY - Abstract
Apoptotic leukocytes are endowed with immunomodulatory properties that can be used to enhance hematopoietic engraftment and prevent graft-versus-host disease (GvHD). This apoptotic cell-induced tolerogenic effect is mediated by host macrophages and not recipient dendritic cells or donor phagocytes present in the bone marrow graft as evidenced by selective cell depletion and trafficking experiments. Furthermore, apoptotic cell infusion is associated with TGF-β-dependent donor CD4
+ CD25+ T-cell expansion. Such cells have a regulatory phenotype (CD62Lhigh and intracellular CTLA-4+ ), express high levels of forkhead-box transcription factor p3 (Foxp3) mRNA and exert ex vivo suppressive activity through a cell-to-cell contact mechanism. In vivo CD25 depletion after apoptotic cell infusion prevents the apoptotic cell-induced beneficial effects on engraftment and GvHD occurrence. This highlights the role of regulatory T cells in the tolerogenic effect of apoptotic cell infusion. This novel association between apoptosis and regulatory T-cell expansion may also contribute to preventing deleterious autoimmune responses during normal turnover.Cell Death and Differentiation (2006) 13, 41–52. doi:10.1038/sj.cdd.4401699; published online 17 June 2005 [ABSTRACT FROM AUTHOR]- Published
- 2006
- Full Text
- View/download PDF
25. Effect of an auditory stress on peritoneal and alveolar cells in C57 BL/6J mice of advanced age
- Author
-
Wazieres, B. de, Harraga, S., Spehner, V., Bloy, Ch., Dupond, J. L., Vuitton, D. A., and Seilles, E.
- Abstract
The aim of this study was to analyse the effects of auditory stress on peritoneal and alveolar macrophages in C57 BL/6J mice of advanced age, and to compare the results to those obtained in old mice submitted to a sham stress, and to those observed in young mice submitted to the same auditory stress. We used a chemiluminescence assay to measure the production of free oxygen radicals (FOR) by macrophages. Eight 22 month-old mice were exposed to a sound stress of 110 dB for three consecutive nights; nine were submitted to a sham stress. The results were compared to those obtained in young (8 week-old) mice, 21 submitted to noise stress, and 17 controls. The corticosterone level was not increased after stress in any group. FOR production in old mice was significantly higher than that in young mice. Stress did not induce significant changes in FOR production by alveolar cells in young mice; however, the FOR production by alveolar cells was significantly higher in the stressed group than in the control group of old mice. These results show that noise stress is associated with modifications of macrophage functions that are influenced by cell localization, the behaviour of alveolar and peritoneal macrophages of old mice being clearly different in our experimental model. Copyright © 2000 John Wiley & Sons, Ltd.
- Published
- 2000
26. Synthesis of new pyrrolo[1,2-d][1,2,4]triazines and thiazolo[3,4-d][1,2,4]-triazines as immunostimulating agents
- Author
-
Issartel, V., Spehner, V., Coudert, P., Seilles, E., and Couquelet, J.
- Published
- 1998
- Full Text
- View/download PDF
27. Gall-bladder - the Predominant Source of Bile Iga in Man
- Author
-
UCL, Vuitton, DA., Seilles, E., Claude, P., Sava, P., Delacroix, Dominique L., UCL, Vuitton, DA., Seilles, E., Claude, P., Sava, P., and Delacroix, Dominique L.
- Published
- 1985
28. [Biology of papillomavirus infections. IV. Sero-epidemiological data]
- Author
-
Seilles E, Greslin I, and CHRISTIANE MOUGIN
- Subjects
Tumor Virus Infections ,DNA, Viral ,Papillomavirus Infections ,Humans ,Reproducibility of Results ,Serologic Tests ,Papillomaviridae - Abstract
Serological assays using synthetic peptides or recombinant proteins to identify specific HPV infection either fail to correlate with the type of infection or are only able to identify a small percentage of infected individuals. But genetically engineered Virus Like Particles (VLP) seem useful to develop Elisas for serological diagnosis of HPV infection and antibodies to VLP appear to correlate well with HPV DNA presence. The levels of secretory immunoglobulins in genital secretions would provide a better indicator of HPV infection, but reproducibility and standardization of the detection methods are unresolved. The clinical relevance of serologic responses is still questionable, since frequency and titer of several types of antibodies generated against HPV show a great variability which is dependent on the HPV type specificity, on the recognized epitopes and on the type of samples. However the detection of neutralizing antibodies associated with disease recurrence and antibodies raised against HPV16 E6 and E7 peptides found to react with sera of cancer patients, needs to pay attention.
29. [Biology of the papillomavirus infections: V. Vaccine developments]
- Author
-
Seilles E, Riethmuller D, and CHRISTIANE MOUGIN
- Subjects
Cytotoxicity, Immunologic ,Oncogene Proteins ,Papillomavirus Infections ,Vaccination ,Uterine Cervical Neoplasms ,Viral Vaccines ,Antibodies, Viral ,Tumor Virus Infections ,Viral Proteins ,DNA, Viral ,Animals ,Humans ,Female ,Papillomavirus Vaccines ,Papillomaviridae ,Precancerous Conditions ,T-Lymphocytes, Cytotoxic - Abstract
Several genotypes of human papillomaviruses (HPV) are recognised as aetiologic factors for cervical cancer, and viral DNA account for more 99% of cases. Thus, prevention of HPV infection by, for example, types 16 and 18, should reduce the world-wide incidence of cervical cancer. Many strategies are being developed for the control of HPV-associated lesions of the uterine cervix: prophylactic vaccines which elicit neutralizing antibodies to prevent HPV infection, and therapeutic vaccines which induce a T-cytotoxic response to early viral oncoproteins. Experimental trials are being conducted to test mucosal immunization with an ideal antigen delivery system. Vaccination strategies elicit a protective antibody response in animal species, but in humans, strategies which are likely to be effective in the control of HPV-associated preneoplastic and neoplastic lesions of the uterine cervix are still under investigation.
30. [Serum and salivary immunoglobins A in atopic dermatitis. Prospective and comparative case control study]
- Author
-
Jm, Voltz, Molé C, François Aubin, Gibey R, Faivre B, Seilles E, and Humbert P
- Subjects
Adult ,Male ,Adolescent ,Fluoroimmunoassay ,IgA Deficiency ,Middle Aged ,Dermatitis, Atopic ,Immunoglobulin A ,Eosinophils ,Leukocyte Count ,Nephelometry and Turbidimetry ,Case-Control Studies ,Immunoglobulin A, Secretory ,Humans ,Female ,Prospective Studies ,Child ,Saliva ,Aged - Abstract
IgA system has been poorly studied in patients with atopic dermatitis (AD). Previous studies have showed that a transient serum IgA deficiency in infancy could lead to atopic disease. In addition, decrease in salivary IgA has been demonstrated in patients with AD. The purpose of our work was to study the IgA system both in serum saliva in patient with AD.We conducted a controlled prospective study from January 1994 to May 1996. 46 patients with AD and 52 healthy volunteers matched for sex and age were included. Atopic patients fulfilled at least three major and three minor features defined by Hanifin and Rajka. None above atopic criteria were present in the control group. Saliva was collected using a small cylinder of a cotton-wool-like substance (Salivette) kept in the buccal fold. Serum and saliva samples were assayed for IgA using standard nephelometric method and time-resolved immunofluorometric assay. Secretory IgA were assayed by a sandwich-type enzyme linked immunosorbent assay. Blood eosinophils and serum IgE were also evaluated.IgA and secretory IgA were detected in all serum and saliva collected. No statistically significant difference were observed in serum or in saliva for both IgA and secretory IgA between patients with AD and controls. As expected, blood eosinophils and serum IgE were significantly increased in patients with AD.None patients (atopic or control) exhibited IgA deficiency. Although no statistically significant, a trend to higher concentrations of serum and salivary IgA was observed in patients with AD suggesting a stimulation of mucosa-associated lymphoid tissue in these patients.
31. RT-PCR in situ directe avec amorces marquées pour la détection d'ARN du virus de l'hépatite C
- Author
-
Bettinger, D, Mougin, C, Fouqué, B, Monnod, B, Seillès, E, Kantelip, B, and Lab, M
- Published
- 1997
- Full Text
- View/download PDF
32. ChemInform Abstract: New 7-Hydroxy-1,3-diazabicyclo(3.3.0)octane Derivatives: Evaluation of Their in vitro Immunomodulating Effects.
- Author
-
ISSARTEL, V., SPEHNER, V., BAHAJI, H., SEILLES, E., and COUQUELET, J.
- Published
- 1996
- Full Text
- View/download PDF
33. Light chains of immunoglobulins in human secretions
- Author
-
Mole, C. M., Bene, M. C., Montagne, P. M., and Seilles, E.
- Published
- 1994
- Full Text
- View/download PDF
34. Imidazo[2,1- b]thiazole derivatives. XI. Modulation of the CD 2-receptor of human T trypsinized lymphocytes by several imidazo[2,1- b]thiazoles
- Author
-
Harraga, S, Nicod, L, Drouhin, JP, Xicluna, A, Panouse, JJ, Seilles, E, and Robert, JF
- Published
- 1994
- Full Text
- View/download PDF
35. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
- Author
-
Xavier Cahu, Maxime Desmarets, Thibaut Leguay, Philippe Saas, Victoria Raggueneau, Delphine Binda, Maria Alessandra Rosenthal, Chrystelle Vidal, Olivier Adotevi, Fanny Angelot-Delettre, Françoise Solly, Anne-Cécile Galoisy, Alice Garnier, Sylvie Daliphard, Estelle Guérin, Marie-Pierre Gourin, Karim Maloum, Véronique Harrivel, Edouard Cornet, Felipe Suarez, Jacques Vargaftig, Fabrice Jardin, Caroline Mayeur-Rousse, Sylvain Thepot, Maïder Pagadoy, Thorsten Braun, Bernard Drenou, Yuriy Drebit, Marc Maynadié, Caroline Basle, Zehaira Benseddik, Frédéric Féger, Jean Feuillard, Christian Recher, Etienne Lengliné, Catherine Cordonnier, Rémi Letestu, Mathieu Puyade, Isabelle Arnoux, Remy Gressin, Nathalie Contentin, Jerome Tamburini, Pascale Saussoy, Mary Callanan, Elodie Dindinaud, Pierre-Simon Rohrlich, Julien Guy, Hind Bennani, Tony Petrella, Vincent Foissaud, Johann Rose, Natacha Maillard, Lucile Baseggio, Magali Le Garff-Tavernier, Vincent Barlogis, Denis Guyotat, Yohan Desbrosses, Caroline Bonmati, Damien Roos-Weil, Michel Ticchioni, Sandrine Puyraimond, Norbert Vey, Adriana Plesa, Blandine Guffroy, Daniel Lusina, Bérengère Gruson, Anne Roggy, Véronique Salaun, Eric Deconinck, Jean-Yves Cahn, Nathalie Jacques, Caroline Bret, Florian Renosi, Marie-Christine Béné, Alice Eischen, Stefan Wickenhauser, Benjamin Papoular, Francine Garnache-Ottou, François-Xavier Gros, Vahid Asnafi, Celia Salanoubat, Blandine Bénet, Elisabeth Macintyre, Lou Soret, Orianne Wagner-Ballon, Mohamad Mohty, Elsa Bera, Nicolas Freynet, Ludovic Lhermitte, Franck Trimoreau, Claude Preudhomme, Christophe Roumier, Sébastien Maury, Sabrina Bouyer, Eve Poret, Mikael Roussel, Romaric Lacroix, Christine Arnoulet, Françoise Schillinger, Patricia Okamba, Christine Lefebvre, Didier Blaise, Nicolas Lechevalier, Sabine Brechignac, Christophe Ferrand, Estelle Seilles, Richard Veyrat-Masson, Giorgia Battipaglia, Denis Caillot, Véronique Latger-Cannard, Bruno Quesnel, Didier Bouscary, Sophie Brun, Agathe Debliquis, Marie Loosveld, Franck Geneviève, Carinne Lafon, Lydia Campos, Thierry Fest, Ouda Ghoual, Marie-Christine Jacob, Pierre Peterlin, Valérie Bardet, Anne Arnaud, Véronique Dorvaux, Sabeha Biichle, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre d'Investigation Clinique de Besançon (Inserm CIC 1431), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Institut Necker Enfants-Malades (INEM - UM 111 (UMR 8253 / U1151)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Institut de génétique humaine (IGH), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), ANR-11-LABX-0024,ParaFrap,Alliance française contre les maladies parasitaires(2011), European Project: IC18CT980373, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service de biologie hématologique, Garnache-Ottou, F., Vidal, C., Biichle, S., Renosi, F., Poret, E., Pagadoy, M., Desmarets, M., Roggy, A., Seilles, E., Soret, L., Schillinger, F., Puyraimond, S., Petrella, T., Preudhomme, C., Roumier, C., Macintyre, E. A., Harrivel, V., Desbrosses, Y., Gruson, B., Genevieve, F., Thepot, S., Drebit, Y., Leguay, T., Gros, F. -X., Lechevalier, N., Saussoy, P., Salaun, V., Cornet, E., Benseddik, Z., Veyrat-Masson, R., Wagner-Ballon, O., Salanoubat, C., Maynadie, M., Guy, J., Caillot, D., Jacob, M. -C., Cahn, J. -Y., Gressin, R., Rose, J., Quesnel, B., Guerin, E., Trimoreau, F., Feuillard, J., Gourin, M. -P., Plesa, A., Baseggio, L., Arnoux, I., Vey, N., Blaise, D., Lacroix, R., Arnoulet, C., Benet, B., Dorvaux, V., Bret, C., Drenou, B., Debliquis, A., Latger-Cannard, V., Bonmati, C., Bene, M. -C., Peterlin, P., Ticchioni, M., Rohrlich, P. -S., Arnaud, A., Wickenhauser, S., Bardet, V., Brechignac, S., Papoular, B., Raggueneau, V., Vargaftig, J., Letestu, R., Lusina, D., Braun, T., Foissaud, V., Tamburini, J., Bennani, H., Freynet, N., Cordonnier, C., Le Garff-Tavernier, M., Jacques, N., Maloum, K., Roos-Weil, D., Bouscary, D., Asnafi, V., Lhermitte, L., Suarez, F., Lengline, E., Feger, F., Battipaglia, G., Mohty, M., Bouyer, S., Ghoual, O., Dindinaud, E., Basle, C., Puyade, M., Lafon, C., Fest, T., Roussel, M., Cahu, X., Bera, E., Daliphard, S., Jardin, F., Campos, L., Solly, F., Guyotat, D., Galoisy, A. -C., Eischen, A., Mayeur-Rousse, C., Guffroy, B., Recher, C., Loosveld, M., Garnier, A., Barlogis, V., Rosenthal, M. A., Brun, S., Contentin, N., Maury, S., Callanan, M., Lefebvre, C., Maillard, N., Okamba, P., Ferrand, C., Adotevi, O., Saas, P., Angelot-Delettre, F., Binda, D., and Deconinck, E.
- Subjects
Oncology ,Vincristine ,medicine.medical_specialty ,Myeloid ,Cyclophosphamide ,Clinical Trials and Observations ,medicine.medical_treatment ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Hematopoietic stem cell transplantation ,Plasmacytoid dendritic cell ,Immunophenotyping ,Clonal Evolution ,03 medical and health sciences ,0302 clinical medicine ,Bone Marrow ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Neoplasm Metastasis ,Neoplasm Staging ,030304 developmental biology ,Chromosome Aberrations ,0303 health sciences ,Leukemia ,business.industry ,Hematopoietic Stem Cell Transplantation ,Disease Management ,Myeloid leukemia ,Dendritic Cells ,Hematology ,Prognosis ,medicine.disease ,Blood Cell Count ,3. Good health ,Transplantation ,Treatment Outcome ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Acute Disease ,business ,Biomarkers ,medicine.drug - Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia for which we developed a nationwide network to collect data from new cases diagnosed in France. In a retrospective, observational study of 86 patients (2000-2013), we described clinical and biological data focusing on morphologies and immunophenotype. We found expression of markers associated with plasmacytoid dendritic cell origin (HLA-DRhigh, CD303+, CD304+, and cTCL1+) plus CD4 and CD56 and frequent expression of isolated markers from the myeloid, B-, and T-lymphoid lineages, whereas specific markers (myeloperoxidase, CD14, cCD3, CD19, and cCD22) were not expressed. Fifty-one percent of cytogenetic abnormalities impact chromosomes 13, 12, 9, and 15. Myelemia was associated with an adverse prognosis. We categorized chemotherapeutic regimens into 5 groups: acute myeloid leukemia (AML)–like, acute lymphoid leukemia (ALL)–like, lymphoma (cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP])–like, high-dose methotrexate with asparaginase (Aspa-MTX) chemotherapies, and not otherwise specified (NOS) treatments. Thirty patients received allogeneic hematopoietic cell transplantation (allo-HCT), and 4 patients received autologous hematopoietic cell transplantation. There was no difference in survival between patients receiving AML-like, ALL-like, or Aspa-MTX regimens; survival was longer in patients who received AML-like, ALL-like, or Aspa-MTX regimens than in those who received CHOP-like regimens or NOS. Eleven patients are in persistent complete remission after allo-HCT with a median survival of 49 months vs 8 for other patients. Our series confirms a high response rate with a lower toxicity profile with the Aspa-MTX regimen, offering the best chance of access to hematopoietic cell transplantation and a possible cure.
- Published
- 2019
36. Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape
- Author
-
Zalmaï L, Viailly PJ, Biichle S, Cheok M, Soret L, Angelot-Delettre F, Petrella T, Collonge-Rame MA, Seilles E, Geffroy S, Deconinck E, Daguindau E, Bouyer S, Dindinaud E, Baunin V, Le Garff-Tavernier M, Roos-Weil D, Wagner-Ballon O, Salaun V, Feuillard J, Brun S, Drenou B, Mayeur-Rousse C, Okamba P, Dorvaux V, Tichionni M, Rose J, Rubio MT, Jacob MC, Raggueneau V, Preudhomme C, Saas P, Ferrand C, Adotevi O, Roumier C, Jardin F, Garnache-Ottou F, and Renosi F
- Subjects
- Cell Proliferation, Humans, Mutation, Phenotype, Dendritic Cells, Leukemia, Myeloid, Acute genetics
- Abstract
Neoplasms involving plasmacytoid Dendritic Cells (pDCs) include Blastic pDC Neoplasms (BPDCN) and other pDC proliferations, where pDCs are associated with myeloid malignancies: most frequently Chronic MyeloMonocytic Leukemia (CMML) but also Acute Myeloid Leukemia (AML), hereafter named pDC-AML. We aimed to determine the reactive or neoplastic origin of pDCs in pDC-AML, and their link with the CD34+ blasts, monocytes or conventional DCs (cDCs) associated in the same sample, by phenotypic and molecular analyses (targeted NGS, 70 genes). We compared 15 pDC-AML at diagnosis with 21 BPDCN and 11 normal pDCs from healthy donors. CD45low CD34+ blasts were found in all cases (10-80% of medullar cells), associated with pDCs (4-36%), monocytes in 14 cases (1-10%) and cDCs (2 cases, 4.8-19%). pDCs in pDC-AML harbor a clearly different phenotype from BPDCN: CD4+ CD56- in 100% of cases, most frequently CD303+, CD304+ and CD34+; lower expression of cTCL1 and CD123 with isolated lymphoid markers (CD22/CD7/CD5) in some cases, suggesting a pre-pDC stage. In all cases, pDCs, monocytes and cDC are neoplastic since they harbor the same mutations as CD34+ blasts. RUNX1 is the most commonly mutated gene: detected in all AML with minimal differentiation (M0-AML) but not in the other cases. Despite low number of cases, the systematic association between M0-AML, RUNX1 mutations and an excess of pDC is puzzling. Further evaluation in a larger cohort is required to confirm RUNX1 mutations in pDC-AML with minimal differentiation and to investigate whether it represents a proliferation of blasts with macrophage and DC progenitor potential.
- Published
- 2021
- Full Text
- View/download PDF
37. Lymphoblastic T Cells and Mature NK Cells With the Same TCRγ Rearrangement: A Common Origin?
- Author
-
Roggy A, Biichle S, Ferrand C, Renosi F, Larosa F, Deconinck E, Daguindeau E, Collonge Rame MA, Schillinger F, Seilles E, and Garnache-Ottou F
- Published
- 2021
- Full Text
- View/download PDF
38. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
- Author
-
Garnache-Ottou F, Vidal C, Biichlé S, Renosi F, Poret E, Pagadoy M, Desmarets M, Roggy A, Seilles E, Soret L, Schillinger F, Puyraimond S, Petrella T, Preudhomme C, Roumier C, MacIntyre EA, Harrivel V, Desbrosses Y, Gruson B, Geneviève F, Thepot S, Drebit Y, Leguay T, Gros FX, Lechevalier N, Saussoy P, Salaun V, Cornet E, Benseddik Z, Veyrat-Masson R, Wagner-Ballon O, Salanoubat C, Maynadié M, Guy J, Caillot D, Jacob MC, Cahn JY, Gressin R, Rose J, Quesnel B, Guerin E, Trimoreau F, Feuillard J, Gourin MP, Plesa A, Baseggio L, Arnoux I, Vey N, Blaise D, Lacroix R, Arnoulet C, Benet B, Dorvaux V, Bret C, Drenou B, Debliquis A, Latger-Cannard V, Bonmati C, Bene MC, Peterlin P, Ticchioni M, Rohrlich PS, Arnaud A, Wickenhauser S, Bardet V, Brechignac S, Papoular B, Raggueneau V, Vargaftig J, Letestu R, Lusina D, Braun T, Foissaud V, Tamburini J, Bennani H, Freynet N, Cordonnier C, Le Garff-Tavernier M, Jacques N, Maloum K, Roos-Weil D, Bouscary D, Asnafi V, Lhermitte L, Suarez F, Lengline E, Féger F, Battipaglia G, Mohty M, Bouyer S, Ghoual O, Dindinaud E, Basle C, Puyade M, Lafon C, Fest T, Roussel M, Cahu X, Bera E, Daliphard S, Jardin F, Campos L, Solly F, Guyotat D, Galoisy AC, Eischen A, Mayeur-Rousse C, Guffroy B, Recher C, Loosveld M, Garnier A, Barlogis V, Rosenthal MA, Brun S, Contentin N, Maury S, Callanan M, Lefebvre C, Maillard N, Okamba P, Ferrand C, Adotevi O, Saas P, Angelot-Delettre F, Binda D, and Deconinck E
- Subjects
- Acute Disease, Biomarkers, Blood Cell Count, Bone Marrow pathology, Chromosome Aberrations, Clonal Evolution genetics, Dendritic Cells metabolism, Disease Management, Hematopoietic Stem Cell Transplantation, Humans, Immunophenotyping, Leukemia etiology, Leukemia metabolism, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Treatment Outcome, Dendritic Cells pathology, Leukemia diagnosis, Leukemia therapy
- Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia for which we developed a nationwide network to collect data from new cases diagnosed in France. In a retrospective, observational study of 86 patients (2000-2013), we described clinical and biological data focusing on morphologies and immunophenotype. We found expression of markers associated with plasmacytoid dendritic cell origin (HLA-DRhigh, CD303+, CD304+, and cTCL1+) plus CD4 and CD56 and frequent expression of isolated markers from the myeloid, B-, and T-lymphoid lineages, whereas specific markers (myeloperoxidase, CD14, cCD3, CD19, and cCD22) were not expressed. Fifty-one percent of cytogenetic abnormalities impact chromosomes 13, 12, 9, and 15. Myelemia was associated with an adverse prognosis. We categorized chemotherapeutic regimens into 5 groups: acute myeloid leukemia (AML)-like, acute lymphoid leukemia (ALL)-like, lymphoma (cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP])-like, high-dose methotrexate with asparaginase (Aspa-MTX) chemotherapies, and not otherwise specified (NOS) treatments. Thirty patients received allogeneic hematopoietic cell transplantation (allo-HCT), and 4 patients received autologous hematopoietic cell transplantation. There was no difference in survival between patients receiving AML-like, ALL-like, or Aspa-MTX regimens; survival was longer in patients who received AML-like, ALL-like, or Aspa-MTX regimens than in those who received CHOP-like regimens or NOS. Eleven patients are in persistent complete remission after allo-HCT with a median survival of 49 months vs 8 for other patients. Our series confirms a high response rate with a lower toxicity profile with the Aspa-MTX regimen, offering the best chance of access to hematopoietic cell transplantation and a possible cure., (© 2019 by The American Society of Hematology.)
- Published
- 2019
- Full Text
- View/download PDF
39. Altered thymic CD4 + T-cell recovery after allogeneic hematopoietic stem cell transplantation is critical for nocardiosis.
- Author
-
Roussel X, Daguindau E, Berceanu A, Desbrosses Y, Saas P, Ferrand C, Seilles E, Pouthier F, Deconinck E, and Larosa F
- Subjects
- Adult, CD4 Lymphocyte Count, CD4-Positive T-Lymphocytes immunology, Case-Control Studies, Female, Hematologic Neoplasms immunology, Hematopoiesis physiology, Humans, Immunity, Cellular physiology, Immunocompromised Host, Male, Middle Aged, Opportunistic Infections etiology, Opportunistic Infections immunology, Retrospective Studies, Risk Factors, Thymus Gland pathology, Transplantation Conditioning adverse effects, Transplantation, Homologous, CD4-Positive T-Lymphocytes pathology, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation adverse effects, Immune Reconstitution physiology, Nocardia Infections etiology, Nocardia Infections immunology, Thymus Gland immunology
- Abstract
Purpose of the Study: Nocardia affects immunocompromised human host exhibiting an altered cell-mediated immunity. Infectious risk after allogeneic hematopoietic cell transplantation (AHCT) is significantly correlated to the recovery status of donor-derived immune system, especially CD4
+ T-cells reconstitution and thymopoiesis. The purpose of this paper is to highlight a lack of cell-mediated immunity recovery for patients presenting a nocardiosis compared to a control cohort., Patients and Methods: This is a case control retrospective monocentric study. We retrospectively analyzed a monocentric cohort of 15 cases of nocardiosis after AHCT and we explored the degree of patients' immunosuppression by phenotyping circulating lymphoid subpopulations, including NK cells, CD8+ T-cells, CD4+ T-cells and CD19+ B-cells. We focused on CD4+ T-cell subsets to appreciate thymic output, especially on naive CD4+ T-cells (NTE, CD45RA+ /RO- CD4+ T-cells) and recent thymic emigrants (RTE, CD4+ CD45RA+ /RO- /CD31+ ). Infected patients were paired with a control cohort of patients with identical transplantation characteristics screened on hematological disease, AHCT conditioning, primary graft-versus-host disease (GHVD) prophylaxis, graft type, sex, age, and season at the AHCT and data concerning immunological reconstitution were compared., Results: At onset of nocardiosis, circulating lymphocytes and CD4+ T-cells means count were respectively 730/μL and 162/μL. CD8+ T-cells, CD56+ NK cells and CD19+ B-cells means count were respectively 362/μL, 160/μL, 112/μL. CD4+ T-cells subpopulations, naïve CD4+ T-cells production was impaired with NTE and RTE means count at 26/μL and 11/μL respectively. Comparison between nocardiosis cohort and control cohort over time highlight significant lower cellular count for lymphocytes, CD4+ T-cells, NTE and RTE with p = 0.001, p < 0.001, p < 0.001, p < 0.001 respectively., Conclusion: Immune recovery monitoring follow-up after AHCT is of particular importance to identify patients susceptible to develop Nocardiosis. Efficient microbiological investigations toward Nocardia such PCR should be used in case of compatible clinical presentation., (Copyright © 2019 Elsevier Masson SAS. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
40. [Acquired C1 esterase inhibitor deficiency via bradykinin-mediated angioedema: Four cases].
- Author
-
Jacquin-Porretaz C, Castelain F, Daguindau E, Seilles E, Nardin C, Aubin F, and Pelletier F
- Subjects
- Abdominal Pain etiology, Aged, Angioedema chemically induced, Angioedema diagnosis, Angioedema immunology, Angioedemas, Hereditary diagnosis, Angiotensin II Type 1 Receptor Blockers adverse effects, Angiotensin-Converting Enzyme Inhibitors adverse effects, Autoimmune Diseases chemically induced, Autoimmune Diseases diagnosis, Autoimmune Diseases immunology, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell immunology, Lymphoma, B-Cell, Marginal Zone immunology, Male, Middle Aged, Paraproteinemias immunology, Angioedema etiology, Autoantibodies immunology, Autoimmune Diseases etiology, Bradykinin physiology, Complement C1 Inhibitor Protein immunology, Leukemia, Lymphocytic, Chronic, B-Cell complications, Lymphoma, B-Cell, Marginal Zone complications, Paraproteinemias complications
- Abstract
Background: Acquired C1-esterase inhibitor (C1-INH) deficiency angioedema (C1-INH-AAE) is a form of bradykinin-mediated angioedema. This rare disorder is due to acquired consumption of C1-INH, hyperactivation of the classic pathway of human complement, and potentially fatal recurrent angioedema symptoms. Clinical symptoms of C1-INH-AAE are very similar to those of hereditary angioedema (HAE) but usually appear after the fourth decade of life and induce abdominal pain less frequently. Laboratory tests are essential in establishing the diagnosis with low levels or abnormal structure and function of C1-INH. Most patients present C1-INH autoantibodies. Furthermore, C1q is reduced in AAE, contrary to HAE. The long-term prognosis is determined by associated hematologic malignancies., Patients and Methods: We report 4 cases of C1-INH-AAE associated with lymphoproliferative disorders referred to the Reference Centre for Angioedema of Besançon, France. The patients were aged between 60 and 77 years. C1 INH antibodies were found in three patients. Symptoms were triggered by angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) in 3 patients. Hematologic malignancy was present at diagnosis (one case of chronic lymphoid leukemia) or was diagnosed during follow-up (one case of indolent marginal zone non-Hodgkin lymphoma and two cases of monoclonal gammopathy)., Discussion: C1-INH-AAE induced by ACE inhibitors or ARBs may be associated with hematologic malignancies. This form of revelation does not necessarily indicate a diagnosis of ACE or ARBs angioedema, and screening should therefore be performed for C1 Inh and C1q. An underlying hematologic malignancy should be routinely sought and the long-term prognosis determined., (Copyright © 2018 Elsevier Masson SAS. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
41. Increased levels of circulating platelet-derived microparticles are associated with metastatic cutaneous melanoma.
- Author
-
Moreau J, Pelletier F, Biichle S, Mourey G, Puyraveau M, Badet N, Caubet M, Laresche C, Garnache-Ottou F, Saas P, Seilles E, and Aubin F
- Subjects
- Biomarkers, Tumor blood, Blood Coagulation, Humans, Melanoma secondary, Neoplasm Staging, Predictive Value of Tests, Skin Neoplasms pathology, Tumor Burden, Blood Platelets, Cell-Derived Microparticles, Melanoma blood, Skin Neoplasms blood
- Abstract
We investigated the plasma levels of PMPs in patients with 45 stage III and 45 stage IV melanoma. PMPs were characterised by flow cytometry and their thrombogenic activity. We also investigated the link between PMPs circulating levels and tumor burden. The circulating levels of PMPs were significantly higher in stage IV (8500 μL
-1 ) than in patients with stage III (2041 μL-1 ) melanoma (P=.0001). We calculated a highly specific (93.3%) and predictive (91.7%) cut-off value (5311 μL-1 ) allowing the distinction between high-risk stage III and metastatic stage IV melanoma. The thrombogenic activity of PMPs was significantly higher in patients with stage IV melanoma (clotting time: 40.7 second vs 65 second, P=.0001). There was no significant association between the radiological tumoral syndrome and the plasma level of PMPs. Our data suggest the role of PMPs in metastatic progression of melanoma., (© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)- Published
- 2017
- Full Text
- View/download PDF
42. How to quantify microparticles in RBCs? A validated flow cytometry method allows the detection of an increase in microparticles during storage.
- Author
-
Gamonet C, Mourey G, Aupet S, Biichle S, Petitjean R, Vidal C, Pugin A, Naegelen C, Tiberghien P, Morel P, Angelot-Delettre F, Seilles E, Saas P, Bardiaux L, and Garnache-Ottou F
- Subjects
- Female, Humans, Male, Time Factors, Blood Preservation, Cell-Derived Microparticles, Cryopreservation, Erythrocytes, Flow Cytometry methods
- Abstract
Background: The procoagulant and proinflammatory microparticles (MPs) released during storage of packed red blood cells (pRBCs) can potentially modify transfusion benefits. A robust method to quantify MPs in pRBCs is needed to evaluate their impact in clinical trials., Study Design and Methods: The objective was to validate the preanalytic conditions required to prepare pRBC supernatant as well as a method to quantify and evaluate MP variations over 42 days of pRBC storage.A flow cytometry method with size-calibrated beads was developed and fully validated. Quantification of MPs in pRBCs (n = 109) was assessed during short-term (7 days) and long-term (42 days) storage at 4°C, during short-term storage (8 hours) at room temperature, and after 2 years frozen., Results: Repeatability, reproducibility, and linearity of the quantification method were validated, and variations during conservation are presented. There was high variability in RBC (erythrocyte) MP (ERMP) and platelet MP (PMP) levels between RBC units, depending on the filter used for leukocyte reduction. During the 42 days of storage at 4°C, significant increases in ERMPs and PMPs occurred (from 58 to 138 ERMPs/µL from Day 2 to Day 42; p = 0.0002; and from 326 to 771 PMPs/µL from Day 2 to Day 42; p = 0.00026)., Conclusion: We use a robust method to confirm that ERMPs and PMPs are present to various degrees in pRBCs and that storage for 42 days significantly increases their generation. This method is robust enough to allow MP quantification in pRBCs and is adapted to evaluate the clinical impact of transfused MPs in prospective clinical trials., (© 2017 AABB.)
- Published
- 2017
- Full Text
- View/download PDF
43. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.
- Author
-
Angelot-Delettre F, Roggy A, Frankel AE, Lamarthee B, Seilles E, Biichle S, Royer B, Deconinck E, Rowinsky EK, Brooks C, Bardet V, Benet B, Bennani H, Benseddik Z, Debliquis A, Lusina D, Roussel M, Solly F, Ticchioni M, Saas P, and Garnache-Ottou F
- Subjects
- Adult, Aged, Aged, 80 and over, Animals, Apoptosis, Biomarkers, Tumor genetics, Blotting, Western, Cell Proliferation, Dendritic Cells metabolism, Female, Flow Cytometry, Hematologic Neoplasms metabolism, Hematologic Neoplasms therapy, Humans, In Vitro Techniques, Interleukin-3 Receptor alpha Subunit genetics, Interleukin-3 Receptor alpha Subunit metabolism, Male, Mice, Mice, Inbred NOD, Mice, SCID, Middle Aged, Myeloproliferative Disorders metabolism, Myeloproliferative Disorders therapy, Plasmacytoma metabolism, Plasmacytoma therapy, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, Biomarkers, Tumor metabolism, Dendritic Cells pathology, Hematologic Neoplasms pathology, Interleukin-3 Receptor alpha Subunit antagonists & inhibitors, Myeloproliferative Disorders pathology, Plasmacytoma pathology, Recombinant Fusion Proteins therapeutic use
- Abstract
Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy derived from plasmacytoid dendritic cells. There is currently no accepted standard of care for treating this neoplasm, and therapeutic strategies have never been prospectively evaluated. Since blastic plasmacytoid dendritic cell neoplasm cells express high levels of interleukin-3 receptor α chain (IL3-Rα or CD123), antitumor effects of the interleukin-3 receptor-targeted drug SL-401 against blastic plasmacytoid dendritic cell neoplasm were evaluated in vitro and in vivo. The cytotoxicity of SL-401 was assessed in patient-derived blastic plasmacytoid dendritic cell neoplasm cell lines (CAL-1 and GEN2.2) and in primary blastic plasmacytoid dendritic cell neoplasm cells isolated from 12 patients using flow cytometry and an in vitro cytotoxicity assay. The cytotoxic effects of SL-401 were compared to those of several relevant cytotoxic agents. SL-401 exhibited a robust cytotoxicity against blastic plasmacytoid dendritic cell neoplasm cells in a dose-dependent manner. Additionally, the cytotoxic effects of SL-401 were observed at substantially lower concentrations than those achieved in clinical trials to date. Survival of mice inoculated with a blastic plasmacytoid dendritic cell neoplasm cell line and treated with a single cycle of SL-401 was significantly longer than that of untreated controls (median survival, 58 versus 17 days, P<0.001). These findings indicate that blastic plasmacytoid dendritic cell neoplasm cells are highly sensitive to SL-401, and support further evaluation of SL-401 in patients suffering from blastic plasmacytoid dendritic cell neoplasm., (Copyright© Ferrata Storti Foundation.)
- Published
- 2015
- Full Text
- View/download PDF
44. Increased levels of circulating microparticles are associated with increased procoagulant activity in patients with cutaneous malignant melanoma.
- Author
-
Laresche C, Pelletier F, Garnache-Ottou F, Lihoreau T, Biichlé S, Mourey G, Saas P, Humbert P, Seilles E, and Aubin F
- Subjects
- Adult, Aged, Aged, 80 and over, Endothelial Cells metabolism, Female, Humans, Male, Melanoma pathology, Middle Aged, Neoplasm Staging, Skin Neoplasms pathology, Melanoma, Cutaneous Malignant, Blood Coagulation physiology, Blood Coagulation Factors metabolism, Cell-Derived Microparticles metabolism, Melanoma metabolism, Skin Neoplasms metabolism, Thrombosis metabolism
- Abstract
Microparticles (MPs) are known to be increased in various malignancies and are involved in tumor invasion, angiogenesis, coagulation, and metastasis. We investigated the plasma levels of annexin-V MPs (AV(+)MPs), platelet-derived MPs (PMPs), and endothelial-derived MPs (EMPs) in patients with melanoma (n=129) and in healthy controls (n=49). A functional coagulation test STA Procoag-PPL measuring the clotting time was performed on samples containing MPs to evaluate their procoagulant potential. The plasma levels of PMPs, EMPs, and AV(+)MPs were significantly higher, and the clotting time-PPL was significantly lower in melanoma patients than in healthy controls. The plasma levels of PMPs, EMPs, and AV(+)MPs were higher in stage IV than in the other stages of melanoma, but with no significant difference. In addition, we observed an inverse correlation between PMPs, AV(+)MPs, and clotting times. Our data suggest that MPs are involved in the progression of melanoma and may be associated to melanoma-associated thrombogenesis.
- Published
- 2014
- Full Text
- View/download PDF
45. Intracytoplasmic detection of TCL1--but not ILT7-by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis.
- Author
-
Angelot-Delettre F, Biichle S, Ferrand C, Seilles E, Gaugler B, Harrivel V, Rosenthal-Allieri MA, Deconinck E, Saas P, and Garnache-Ottou F
- Subjects
- Adolescent, Aged, Aged, 80 and over, Blast Crisis blood, Blast Crisis metabolism, Female, Humans, Leukemia, Myeloid, Acute blood, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute metabolism, Male, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma blood, Precursor Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Precursor Cell Lymphoblastic Leukemia-Lymphoma metabolism, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma blood, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma metabolism, Proto-Oncogene Mas, Proto-Oncogene Proteins blood, Receptors, Immunologic blood, Young Adult, Blast Crisis diagnosis, Cytoplasm metabolism, Dendritic Cells metabolism, Flow Cytometry methods, Leukemia diagnosis, Proto-Oncogene Proteins metabolism, Receptors, Immunologic metabolism
- Abstract
Diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) or plasmacytoid dendritic cell leukemia (pDCL) is mainly based on immunophenotypical characterization of leukemic cells in blood or bone marrow samples. We tested by flow cytometry intracellular expression of the proto-oncogene T-cell leukemia 1 (TCL1), as well as membrane and intracellular expression of immunoglobulin-like transcript 7 (ILT7) in 21 pDCL samples and 61 non-pDC acute leukemia samples [i.e., 14 B-acute lymphoblastic leukemia (B-ALL), 9 T-ALL and 38 acute myeloid leukemia (AML)]. TCL1 is highly expressed in all pDCL samples while at a statistically lower level in all B-ALL and 34% of AML. Statistical analysis shows that intensity of TCL1 expression is a good marker for differential diagnosis of pDCL versus other acute leukemia (area under the receiver-operating characteristic curve, [AUC]: 0.96). By contrast, ILT7 positivity is limited to few pDCL samples and cannot be useful for diagnosis purpose. In conclusion, high intracellular intensity of TCL1 expression is currently the best marker for pDC lineage assignment by flow cytometry, which is particularly useful to distinguish pDCL from CD4(+) CD56(+/-) undifferentiated or monoblastic acute leukemia. Thus, intracellular TCL1 detection should be included in acute leukemia diagnosis panels used in hematology laboratories. © 2012 International Society for Advancement of Cytometry., (Copyright © 2012 International Society for Advancement of Cytometry.)
- Published
- 2012
- Full Text
- View/download PDF
46. Correlation between platelet-derived microparticle enumeration by flow cytometry and phospholipid-dependent procoagulant activity in microparticles: the centrifugation step matters!
- Author
-
Stagnara J, Garnache Ottou F, Angelot F, Mourey G, Seilles E, Biichlé S, Saas P, and Racadot E
- Subjects
- Blood Platelets pathology, Cell-Derived Microparticles pathology, Factor Xa metabolism, Fluorometry, Humans, Particle Size, Platelet Count, Thrombin metabolism, Blood Coagulation, Blood Coagulation Tests, Blood Platelets metabolism, Cell-Derived Microparticles metabolism, Centrifugation methods, Flow Cytometry, Phospholipids blood
- Published
- 2012
- Full Text
- View/download PDF
47. [The role of dendritic cells in auto-inflammation seen in psoriasis].
- Author
-
Pelletier F, Angelot F, Garnache-Ottou F, Humbert P, Seilles E, and Aubin F
- Subjects
- Humans, Interferon Type I metabolism, Psoriasis immunology, Signal Transduction, Dendritic Cells physiology, Psoriasis pathology
- Published
- 2010
- Full Text
- View/download PDF
48. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia.
- Author
-
Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E, Salaun V, Garand R, Lepelley P, Maynadié M, Kuhlein E, Deconinck E, Daliphard S, Chaperot L, Beseggio L, Foisseaud V, Macintyre E, Bene MC, Saas P, and Jacob MC
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Biomarkers analysis, Child, Female, Flow Cytometry methods, Humans, Interleukin-3 Receptor alpha Subunit analysis, Lectins, C-Type analysis, Leukemia diagnosis, Leukemia immunology, Leukemia, Myeloid, Acute immunology, Male, Membrane Glycoproteins analysis, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma immunology, Proto-Oncogene Proteins analysis, Receptors, Immunologic analysis, Reverse Transcriptase Polymerase Chain Reaction methods, Statistics, Nonparametric, Algorithms, Dendritic Cells immunology, Leukemia classification
- Abstract
The diagnosis of plasmacytoid dendritic cell leukaemia (pDCL) is based on the immunophenotypic profile: CD4(+) CD56(+) lineage(neg) CD45RA(+)/RO(neg) CD11c(neg) CD116(low) CD123(+) CD34(neg) CD36(+) HLA-DR(+). Several studies have reported pDCL cases that do not express this exact profile or expressing some lineage antigens that could thus be misdiagnosed. This study aimed to validate pDCL-specific markers for diagnosis by flow-cytometry or quantitative reverse transcription polymerase chain reaction on bone marrow samples. Expression of markers previously found in normal pDC was analysed in 16 pDCL, four pDCL presenting an atypical phenotype (apDCL) and 113 non-pDC - lymphoid or myeloid - acute leukaemia. CD123 was expressed at significantly higher levels in pDCL and apDCL. BDCA-2 was expressed on 12/16 pDCL and on 2/4 apDCL, but was never detected in the 113 non-pDC acute leukaemia cases. BDCA-4 expression was found on 13/16 pDCL, but also in 12% of non-pDC acute leukaemia. High levels of LILRA4 and TCL1A transcripts distinguished pDCL and apDCL from all other acute leukaemia (except B-cell acute lymphoblastic leukaemia for TCL1A). We thus propose a diagnosis strategy, scoring first the CD4(+) CD56(+/-) MPO(neg) cCD3(neg) cCD79a(neg) CD11c(neg) profile and then the CD123(high), BDCA-2 and BDCA-4 expression. Atypical pDCL can be also identified this way and non-pDC acute leukaemia excluded: this scoring strategy is useful for diagnosing pDCL and apDCL.
- Published
- 2009
- Full Text
- View/download PDF
49. [Immune monitoring of kidney transplant recipients: can markers predictive of over-immunosuppression be identified?].
- Author
-
Saas P, Courivaud C, Bamoulid J, Garnache-Ottou F, Seilles E, and Ducloux D
- Subjects
- Drug Monitoring, Graft Rejection prevention & control, Humans, Immunosuppressive Agents administration & dosage, Immunosuppressive Agents therapeutic use, Immunosuppressive Agents adverse effects, Kidney Transplantation immunology
- Abstract
While the use of nonspecific immunosuppressive drugs has significantly reduced the incidence of acute graft rejection, the benefits of such therapies on chronic rejection and overall long-term graft survival are uncertain. Persistent excessive immunosuppression after immunosuppressive drug treatment is associated with long-term toxicity including increased incidence of cancers, severe infectious complications and metabolic diseases (for example, diabetes, atherosclerosis). One of our team's aims is to identify immunological factors that can predict such toxicities. We have previously demonstrated that CD4T cell cytopenia was correlated with high risk of cancers and infections as well as atherosclerosis in renal transplant recipients. Now, we are investigating the mechanisms involved in CD4T cell cytopenia. We are also exploring how inflammation and cells from the innate immunity influence the complications associated with kidney transplantation. This was performed through the analysis of gene polymorphism on TLR-4, NOD2/CARD15 receptors and IL-6 promoter and correlation with transplantation outcome. We already correlated IL-6 promoter gene polymorphism at position -174 with new-onset diabetes after transplantation in overweight patients. Identification of gene polymorphisms or factors associated with complications after transplantation may help physicians to determine high-risk recipient profiles and optimize pre- and post-transplantation treatment strategies.
- Published
- 2008
- Full Text
- View/download PDF
50. Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes.
- Author
-
Brillard E, Pallandre JR, Chalmers D, Ryffel B, Radlovic A, Seilles E, Rohrlich PS, Pivot X, Tiberghien P, Saas P, and Borg C
- Subjects
- Adoptive Transfer, Animals, Cells, Cultured, Disease Models, Animal, Female, Flow Cytometry, Forkhead Transcription Factors biosynthesis, Humans, Interferon-gamma biosynthesis, Interleukin-2 pharmacology, Killer Cells, Natural drug effects, Leukocyte Common Antigens biosynthesis, Lymphocyte Culture Test, Mixed, Male, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Knockout, RNA, Messenger genetics, Reverse Transcriptase Polymerase Chain Reaction methods, T-Lymphocytes, Regulatory transplantation, Transplantation, Heterologous, CD28 Antigens physiology, CD4 Antigens biosynthesis, Forkhead Transcription Factors genetics, Killer Cells, Natural immunology, T-Lymphocytes, Regulatory immunology, Transcription, Genetic immunology
- Abstract
Objective: CD4(+)CD25(+) regulatory T lymphocytes (Treg) have been initially shown to prevent organ-specific autoimmunity. It is now accepted that Treg homeostasis depends in part on the peripheral conversion of naïve CD4(+)CD25(-) T cells. This conversion implicates acquisition of the Treg-specific markers, forkhead winged helix protein 3 (Foxp3), after CD28 costimulation. Because natural killer cells (NK) are critical for efficient cytotoxic T-cell priming and TH1 polarization, we investigated their role in Foxp3 induction in CD4(+) T lymphocytes., Materials and Methods: Human CD4(+)CD25(-) T lymphocytes were activated in vitro by CD28 costimulation in the presence of interleukin-2-activated NK. Three days after initial activation, Foxp3 protein and RNA expression were determined by flow cytometry and reverse transcription polymerase chain reaction. In vivo influence of activated NK on Foxp3 expression was studied in an adoptive transfer model of CD45.2(+) CD4(+)CD25(-) lymphocytes into CD45.1(+) mice., Results: Interleukin-2-activated NK decreased Treg conversion of adoptively transferred murine CD4(+)CD25(-) T cells in vivo. Likewise, human-activated NK, but not resting NK, decreased CD28-driven Foxp3 expression in CD4(+)CD25(-) T lymphocytes, while at the same time increasing proliferation and interferon-gamma (IFN-gamma) production. Neutralization of IFN-gamma partially restored Treg conversion and prevented TH1 polarization after CD28 costimulation., Conclusion: The current study suggests that activated NK interfere with CD28-mediated Foxp3 expression in CD4(+)CD25(-) T lymphocytes. Our experiments further underline a molecular interaction between IFN-gamma and Foxp3 downstream of CD28 signaling. Together, these results demonstrate that activated NK play a critical role at the initiation step of immune responses by modulating peripheral Treg differentiation.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.